News
Biotech-startup CEOs are taking more nuanced approaches to going public amid a downturn. Insider talked to the leaders of five privately held biotechs for their views on IPOs in 2023.
Sujal Patel, CEO of Nautilus Biotechnology Nautilus CEO Sujal Patel. (Nautilus Photo) Patel previously helped launch and lead Isilon Systems, which sold to EMC for $2.25 billion in 2010.
Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results